TAKHZYRO 150 mg, Injektionslösung in einer Fertigspritze

7680681780021 CH-68178 Injektionslösung
TAKHZYRO 150 mg, Injektionslösung in einer Fertigspritze
TAKHZYRO 150 mg, Injektionslösung in einer Fertigspritze
TAKHZYRO 150 mg, Injektionslösung in einer Fertigspritze
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Fertigspritze(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
08/07/2026
Summary of Product Characteristics
Français
08/07/2026
Summary of Product Characteristics
Italien
08/07/2026

Detailed composition

Substance Quantity Type Category
lanadelumabum
150.0 MG Substance Wirkstoff (Principe actif)
dinatrii phosphas dihydricus
- Substance HNIDK
acidum citricum monohydricum
- Substance HNIDK
histidinum
- Substance HNIDK
natrii chloridum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
3.46 MG Substance HBESI

Authorization holder

Takeda Pharma AG

8152 Opfikon

Authorization information

Swissmedic authorization number
68178
Drug name
TAKHZYRO, Injektionslösung in einer Fertigspritze
Galenic form
INLFS
ATC Code
B06AC05
Authorization status
Z
Dispensing category
B
First authorization
05/11/2020
Authorization expiration date
31/12/9999
IT Number
02.99.0.
Domain
Human medicine
Field of application
Langzeitprophylaxe von Attacken des hereditären Angioödems

Package details

Description (FR)
TAKHZYRO sol inj 150 mg/ml seringue préremplie
Description (DE)
TAKHZYRO Inj Lös 150 mg/ml Fertigspritze
Market launch
11/04/2024
Narcotic (BTM)
No

Other package sizes (1)

TAKHZYRO sol inj 300 mg/2ml seringue préremplie
1 FESP
GTIN: 7680681780014
View
Buy us a coffee Explore the data